SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Tocagen Inc. (TOCA)

TOCA RSS Feed
Add TOCA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/24/2017 12:28:52 PM - Followers: 0 - Board type: Free - Posts Today: 0

Tocagen Inc. 3030 Bunker Hill Street Suite 230 San Diego, CA 92109 United States 858-412-8400 http://www.tocagen.com Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG). It is also developing Toca 511 & Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.
TOCA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
TOCA News: Quarterly Report (10-q) 08/09/2017 05:19:17 PM
TOCA News: Tocagen Reports Second Quarter 2017 Financial and Business Results 08/09/2017 05:07:00 PM
TOCA News: Current Report Filing (8-k) 08/09/2017 04:12:37 PM
TOCA News: Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9 08/02/2017 04:05:00 PM
TOCA News: Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma 07/24/2017 08:00:00 AM
PostSubject
#1   TOCA buy 15.90 stocktrademan 05/24/17 12:28:52 PM
PostSubject